Find Paid Research Studies in Advance, Indiana

Browse Locations ... United States» ... Indiana» ... Advance

Tivantinib in Treating Patients With Previously Treated Metastatic or Recurrent Malignant Mesothelioma

Conditions: Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma; Stage II Malignant Mesothelioma; Stage III Malignant Mesothelioma; Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

Conditions: Full Iris Defects; Partial Iris Defects
Intervention: Device: Artificial Iris (CustomFlex)
Sponsors: HumanOptics AG; HumanOptics AG
Not yet recruiting - verified May 2013
Aspiring to Awesome- Patient Preference Privacy Selections in EMR

Conditions: EMR; Patient Preference
Intervention: Other: Patient preferences
Sponsors: Indiana University; Indiana University; Department of Health and Human Services; Regenstrief Institute, IU Center for Aging Research
Not yet recruiting - verified May 2013
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients

Condition: Moderate to Severe Chronic Plaque Psoriasis
Interventions: Biological: AbGn-168H; Biological: placebo
Sponsors: AbGenomics B.V Taiwan Branch; AbGenomics B.V Taiwan Branch
Recruiting - verified May 2013
Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Condition: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Drug: GFF MDI (PT003); Drug: GP MDI (PT001); Drug: FF MDI (PT005); Drug: Placebo
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 1)

Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: GFF MDI; Drug: GP MDI; Drug: FF MDI; Drug: Open-label tiotropium bromide inhalation powder; Drug: Placebo MDI
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Not yet recruiting - verified May 2013
Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV

Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides

Conditions: Wrinkles; Rhytides
Intervention: Device: TriActive+ RF
Sponsors: El. En. SpA; El. En. SpA
Recruiting - verified May 2013
Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

Condition: Congestive Heart Failure
Interventions: Drug: D-ribose; Other: Placebo
Sponsors: RiboCor, Inc.; RiboCor, Inc.
Not yet recruiting - verified May 2013
Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

Conditions: Fuchs' Dystrophy; Corneal Edema
Interventions: Drug: loteprednol etabonate; Drug: prednisolone acetate 1%
Sponsors: Cornea Research Foundation of America; Cornea Research Foundation of America
Recruiting - verified May 2013
A Study of IMC-1 In Patients With Fibromyalgia

Conditions: Fibromyalgia; Chronic Pain; Myofascial Pain
Intervention: Drug: IMC-1
Sponsors: Innovative Med Concepts, LLC; Innovative Med Concepts, LLC
Recruiting - verified May 2013
A Multiple Dose Study of LY3023703 in Healthy Participants

Condition: Healthy Volunteers
Interventions: Drug: Placebo; Drug: LY3023703; Drug: Celecoxib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial-2

Condition: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

Conditions: Benign Prostatic Hyperplasia; BPH; Lower Urinary Tract Symptoms (LUTS); LUTS; Enlarged Prostate
Intervention: Drug: NX-1207
Sponsors: Nymox Corporation; Nymox Corporation
Recruiting - verified May 2013
Meaningful Activity Intervention for Persons With Mild Cognitive Impairment

Condition: Mild Cognitive Impairment
Interventions: Behavioral: Daily Enhancement Meaningful Activity (DEMA); Behavioral: Information Support (IS)
Sponsors: Indiana University; Indiana University
Recruiting - verified April 2013
Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia

Condition: Vulvovaginal Atrophy
Interventions: Drug: Estradiol Vaginal Gel; Drug: Vehicle
Sponsors: Warner Chilcott; Warner Chilcott
Recruiting - verified April 2013
The Effect of Gemfibrozil and Ketoconazole on the Amount of LY2409021 in the Bloodstream

Condition: Healthy Volunteers
Interventions: Drug: LY2409021; Drug: Gemfibrozil; Drug: Ketoconazole
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy

Conditions: Hepatic Encephalopathy; Cirrhosis
Interventions: Drug: Rifaximin; Drug: Rifaximin and Lactulose
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals
Recruiting - verified April 2013
An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

Condition: Acne Vulgaris
Intervention: Drug: cortexolone 17α-propionate
Sponsors: Intrepid Therapeutics, Inc.; Intrepid Therapeutics, Inc.
Recruiting - verified April 2013
26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Condition: Chronic Idiopathic Constipation
Interventions: Drug: Elobixibat 10 mg; Drug: Elobixibat 5 mg; Drug: Placebo
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified May 2013
A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia

Condition: Primary Hypercholesterolemia or Mixed Dyslipidemia
Intervention: Device: AMG 145
Sponsors: Amgen; Amgen
Not yet recruiting - verified May 2013
Safety, Tolerability and Efficacy Study of LiRIS® 400mg in Women With Interstitial Cystitis

Condition: Interstitial Cystitis
Interventions: Drug: LiRIS 400 mg; Other: LiRIS Placebo
Sponsors: TARIS Biomedical, Inc.; TARIS Biomedical, Inc.
Recruiting - verified May 2013
Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression

Condition: Traumatic Brain Injury
Interventions: Drug: Buspirone; Drug: Placebo
Sponsors: Indiana University; Indiana University
Recruiting - verified March 2013
Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Condition: Breast Cancer
Intervention: Biological: Margetuximab
Sponsors: MacroGenics; MacroGenics
Recruiting - verified May 2013
Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis

Condition: Actinic Keratosis
Interventions: Drug: Ingenol mebutate gel; Drug: placebo
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified May 2013
Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

Conditions: HIV; HIV Infections
Intervention: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Condition: Hypogonadism
Interventions: Drug: Testosterone Solution; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2013
A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas

Condition: Basal Cell Carcinoma
Interventions: Drug: vismodegib; Drug: vismodegib; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165

Condition: Phenylketonuria
Intervention: Drug: BMN 165
Sponsors: BioMarin Pharmaceutical; BioMarin Pharmaceutical
Recruiting - verified May 2013
SynapDx Autism Gene Expression Analysis Study (STORY)

Condition: Autism
Intervention:
Sponsors: SynapDx; SynapDx
Recruiting - verified May 2013
Growth and Tolerance of Infants Fed Infant Formulas

Condition: Growth and Tolerance
Interventions: Other: Control Formula; Other: Experimental Formula 1; Other: Experimental Formula 2; Other: Human Milk
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified May 2013
Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors

Conditions: Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Malignant Extragonadal Germ Cell Tumor; Malignant Extragonadal Non-Seminomatous Germ Cell Tumor; Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Ovarian Germ Cell Tumor; Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Ovarian Germ Cell Tumor
Intervention: Drug: palifosfamide
Sponsors: Indiana University; Indiana University School of Medicine; ZIOPHARM
Recruiting - verified March 2013
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRANSPORT)

Condition: Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions: Drug: Ivacaftor; Drug: Lumacaftor; Drug: Ivacaftor Placebo; Drug: Lumacaftor Placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2013
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Conditions: Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: idarubicin; Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: rHIgM22 first dose; Drug: rHIgM22 second escalated dose; Drug: rHIgM22 third escalated dose; Drug: rHIgM22 fourth escalated dose; Drug: rHIgM22 fifth escalated dose; Drug: rHIgM22 sixth escalated dose
Sponsors: Acorda Therapeutics; Acorda Therapeutics; PRA International
Recruiting - verified May 2013
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia

Condition: Pneumonia, Bacterial
Interventions: Drug: Amikacin Inhalation Solution (BAY41-6551); Drug: Aerosolized Placebo
Sponsors: Bayer; Bayer; Nektar Therapeutics; Novartis Pharmaceuticals
Recruiting - verified May 2013
Mechanical Debridement Verus Radiofrequency-Based Debridement to Treat Articular Cartilage Lesions With Partial Meniscectomy in the Knee (ACT)

Condition: Chondral Lesion Plus Partial Medial Meniscectomy
Interventions: Device: Mechanical Debridement (Mechanical Shaver); Device: Radiofrequency-Based Debridement
Sponsors: ArthroCare Corporation; ArthroCare Corporation
Recruiting - verified April 2013
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified May 2013
MARLINA : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Linagliptin 5mg
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Generic Database of Moderate Preterm Infants

Conditions: Infant, Newborn; Infant, Moderate Preterm
Intervention:
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified February 2013
Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

Condition: Low Back Pain
Interventions: Drug: Hydrocodone bitartrate extended-release tablets; Drug: Matching placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Condition: Hypertension
Interventions: Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106); Drug: Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 064)

Condition: Advanced or Metastatic Melanoma
Interventions: Biological: Nivolumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Condition: Allergic Rhinitis
Interventions: Drug: BDP Nasal Aerosol; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2013
RISE Adult Medication Study

Conditions: Prediabetes; Type 2 Diabetes
Interventions: Drug: Metformin; Drug: Liraglutide; Drug: Glargine
Sponsors: RISE Study Group; RISE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
RISE Pediatric Medication Study

Conditions: Prediabetes; Type 2 Diabetes
Interventions: Drug: Metformin; Drug: Glargine
Sponsors: RISE Study Group; RISE Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2013
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Conditions: Bladder Cancer; Urothelial Carcinoma
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; OncoGenex Technologies, Inc.
Recruiting - verified May 2013
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Condition: Mantle Cell Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Ibrutinib; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773 Placebo; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773 / BI 1356; Drug: BI 10773; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo; Drug: BI 10773 Placebo; Drug: BI 10773; Drug: BI 10773 / BI 1356 Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Condition: Plaque Psoriasis
Interventions: Drug: Ixekizumab Auto-Injector; Drug: Ixekizumab Prefilled Syringe
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Condition: Gastric Cancer
Interventions: Drug: pertuzumab [Perjeta]; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: cisplatin; Drug: capecitabine; Drug: 5-fluorouracil
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer
Interventions: Drug: porfimer sodium; Procedure: endoscopic ultrasonography; Procedure: photodynamic therapy; Drug: gemcitabine hydrochloride
Sponsors: Indiana University; Indiana University; American Society for Gastrointestinal Endoscopy; Pinnacle Biologics Inc.
Recruiting - verified May 2013
Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Condition: Type 2 Diabetes
Interventions: Drug: lixisenatide (AVE0010); Drug: insulin glulisine (HMR1964)
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients

Condition: Knee Osteoarthritis
Intervention: Device: Compex Rehab
Sponsors: Orthopaedic Research Foundation; Orthopaedic Research Foundation; DJO Incorporated
Recruiting - verified April 2013
Study Evaluating the Effects of Avanafil on Semen Parameters

Condition: Erectile Dysfunction
Interventions: Drug: avanafil; Drug: Placebo
Sponsors: VIVUS, Inc.; VIVUS, Inc.
Recruiting - verified May 2013
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

Conditions: Amnestic Mild Cognitive Impairment; Alzheimer's Disease
Interventions: Drug: Insulin (Humulin® R U-100); Drug: Placebo
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS)
Not yet recruiting - verified May 2013
PK and PD Study of Calcitriol 3 Mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Condition: Plaque Psoriasis
Intervention: Drug: Calcitriol 3 mcg/g ointment
Sponsors: Galderma; Galderma
Recruiting - verified April 2013
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Other: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally); Drug: Statin therapy
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas

Conditions: Neurofibromatosis Type 2; Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham; Genentech
Recruiting - verified May 2013
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

Condition: Hyperlipidemia
Interventions: Drug: AMG 145; Drug: Ezetimibe; Other: Placebo (administered subcutaneously); Other: Placebo (administered orally)
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Condition: Metastatic or Unresectable Cutaneous Melanoma
Interventions: Drug: MEK162; Drug: Dacarbazine
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2013
Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Condition: Community-acquired Bacterial Pneumonia
Interventions: Drug: Solithromycin; Drug: Moxifloxacin
Sponsors: Cempra Pharmaceuticals; Cempra Pharmaceuticals
Recruiting - verified May 2013
ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform

Conditions: Aortic Valve Disorder; Aortic Valve Insufficiency; Aortic Valve Stenosis; Heart Failure; Coronary Artery Disease
Intervention: Device: Edwards Aortic Bioprosthesis Model 11000A Valve
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis

Condition: Knee Osteoarthritis
Interventions: Device: Durolane; Device: PBS
Sponsors: Q-Med AB; Q-Med AB
Recruiting - verified May 2013
Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Condition: Postherpetic Neuralgia
Interventions: Drug: Z160; Drug: Placebo
Sponsors: Zalicus; Zalicus
Recruiting - verified May 2013
Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Condition: Triple Negative Breast Cancer
Interventions: Drug: Tivozanib Hydrochloride; Drug: paclitaxel
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.; Astellas Pharma Inc
Recruiting - verified April 2013
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS)
Intervention: Drug: Treosulfan
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program; Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT); Pediatric Blood and Marrow Transplant Consortium; St. Baldrick's Foundation; medac GmbH
Not yet recruiting - verified May 2013
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Condition: Leukemia Lymphocytic Chronic B-Cell
Interventions: Drug: CC-292; Drug: Rituximab
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.

Condition: CML
Intervention: Drug: AMN107
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

Condition: Dry Eye
Interventions: Drug: Lifitegrast; Drug: Placebo
Sponsors: SARcode Bioscience; SARcode Bioscience
Recruiting - verified May 2013
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

Conditions: Spasticity; Multiple Sclerosis
Interventions: Drug: arbaclofen; Drug: baclofen; Drug: Placebo
Sponsors: Osmotica Pharmaceutical Corporation; Osmotica Pharmaceutical Corporation
Recruiting - verified May 2013
Efficacy and Safety of ISIS TTR Rx in Familial Amyloid Polyneuropathy

Condition: Familial Amyloid Polyneuropathy
Interventions: Drug: ISIS TTR Rx; Drug: Placebo
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals; GlaxoSmithKline
Recruiting - verified April 2013
Essure-NovaSure Post Approval Study

Conditions: Contraception; Prevention of Pregnancy; Menorrhagia
Intervention: Device: Essure - Nova Sure
Sponsors: Conceptus, Inc.; Conceptus, Inc.
Recruiting - verified May 2013
Comprehensive Opioid Management

Condition: Chronic Pain
Interventions: Behavioral: IVR self-management; Behavioral: Opioid monitoring; Other: Enhanced usual care
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2013
Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Condition: Lymphoma, Non-Hodgkin's
Intervention: Drug: PNT2258
Sponsors: Pronai Therapeutics, Inc; Pronai Therapeutics, Inc
Recruiting - verified May 2013
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions: Diabetes Mellitus, Non-Insulin-Dependent; High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg; Drug: Placebo tablet
Sponsors: AstraZeneca; AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization
Recruiting - verified May 2013
Gene Expression in Cumulus Cells to Predict Pregnancy

Condition: Infertility
Interventions: Other: Morphology; Other: GemART assay
Sponsors: Gema Diagnostics; Gema Diagnostics
Recruiting - verified May 2013
Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: tivantinib; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis Participants

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Moderate to Severe Rheumatoid Arthritis Study

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Conditions: Diabetes Mellitus, Type 2; Hyperglycemia
Interventions: Drug: Empagliflozin low dose qd; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose qd; Drug: Empagliflozin low dose bid; Drug: Metformin 500 mg bid; Drug: Empagliflozin high dose bid; Drug: Empagliflozin low dose bid; Drug: Metformin 1000 mg bid; Drug: Metformin 500 mg bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid; Drug: Metformin 1000 mg bid; Drug: Empagliflozin high dose bid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

Condition: Binge Eating Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)

Condition: Hypercholesterolemia
Interventions: Drug: Anacetrapib 100 mg; Drug: Placebo for anacetrapib 100 mg; Drug: Anacetrapib 25 mg; Drug: Placebo for anacetrapib 25 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Interventions: Drug: FOLFOX6m; Device: SIR-Spheres microspheres
Sponsors: Sirtex Medical; Sirtex Medical
Recruiting - verified May 2013
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition: Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment

Condition: Dupuytren's Contracture
Intervention:
Sponsors: Auxilium Pharmaceuticals; Auxilium Pharmaceuticals
Recruiting - verified October 2012
Clinical Investigation of Expanded Designs of a Multifocal IOL

Condition: Cataract
Interventions: Device: Tecnis Multifocal Intraocular Lens; Device: Monofocal Intraocular Lens
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified April 2013
A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/insulin aspart; Drug: insulin degludec; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
NOLAN: Naproxen or Loratadine and Neulasta

Condition: Bone Pain in Stage I - III Breast Cancer
Interventions: Drug: Naproxen; Drug: Loratadine
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Versartis Trial in Children to Assess Long-Acting Growth Hormone

Condition: Pediatric Growth Hormone Deficiency
Intervention: Drug: Experimental: VRS-317
Sponsors: Versartis Inc.; Versartis Inc.
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Baricitinib; Drug: Methotrexate; Drug: Placebo; Drug: Folic Acid
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study in Moderate to Severe Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain

Condition: Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions: Drug: GRT6005 Low-Dose Range; Drug: GRT6005 High-Dose Range; Drug: Placebo; Drug: Oxycodone CR
Sponsors: Forest Laboratories; Forest Laboratories; Grünenthal GmbH
Recruiting - verified May 2013
Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors

Conditions: Recurrent Melanoma; Recurrent Thyroid Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: cabozantinib-s-malate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: CK-2017357; Other: Placebo tablets
Sponsors: Cytokinetics; Cytokinetics
Recruiting - verified May 2013
VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Condition: Postmenopausal Osteoporosis
Interventions: Drug: Teriparatide; Drug: Risedronate; Drug: Placebo; Drug: Calcium; Drug: Vitamin D
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Study to Compare the Effect of Ipilimumab Retreatment With Chemotherapy in Advanced Melanoma

Condition: Melanoma
Interventions: Biological: Ipilimumab; Drug: Chemotherapy
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib

Condition: Non-small Cell Lung Cancer(NSCLC)
Interventions: Drug: AT13387; Drug: Crizotinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified April 2013
Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022 AM4)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Matching placebo to MK-3012; Drug: Glimepiride; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Participants With Type 2 Diabetes Mellitus (MK-3102-018 AM5)

Condition: Type 2 Diabetes Mellitus
Interventions: Drug: MK-3102; Drug: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Conditions: Staphylococcus Aureus Bacteremia; Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Intervention: Drug: Ceftaroline fosamil
Sponsors: Cerexa, Inc.; Cerexa, Inc.
Recruiting - verified May 2013
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Condition: Atrial Fibrillation
Intervention: Other: Patients with Atrial Fibrillation
Sponsors: Janssen Scientific Affairs, LLC; Janssen Scientific Affairs, LLC; Duke Clinical Research Institute
Recruiting - verified May 2013
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV

Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)

Conditions: Rhinitis, Allergic, Perennial; Rhinitis, Allergic, Nonseasonal
Interventions: Biological: MK-8237 tablets; Biological: Placebo tablets; Drug: Rescue Medication: Self-Injectable Epinephrine; Drug: Rescue Medication: Loratadine tablets; Drug: Rescue Medication: Olopatadine ophthalmic drops; Drug: Rescue Medication: Mometasone furoate nasal spray
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

Condition: Chronic Myeloid Leukemia
Intervention: Drug: nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Condition: Multiple Sclerosis (MS)
Interventions: Drug: Laquinimod 0.6 mg; Drug: Matching Placebo; Drug: Laquinimod 1.2 mg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Condition: Hepatitis C
Interventions: Drug: Telaprevir; Drug: Peginterferon alfa-2b; Drug: Ribavirin
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2013
Co-administration of Olodaterol Respimat® andTtiotropium Handihaler®

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium; Drug: Placebo matching Olodaterol; Drug: Tiotropium; Drug: Olodaterol
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia

Condition: High Risk Acute Myeloid Leukemia
Interventions: Drug: CPX-351; Drug: 7+3 (cytarabine and daunorubicin)
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals; The Leukemia and Lymphoma Society
Recruiting - verified May 2013
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment

Condition: Cystic Fibrosis
Interventions: Biological: KB001-A; Biological: Placebo Comparator
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified May 2013
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Phase 2 Study of TD-9855 to Treat Fibromyalgia

Condition: Fibromyalgia
Interventions: Drug: TD-9855 Group 1; Drug: TD-9855 Group 2; Drug: Placebo
Sponsors: Theravance, Inc.; Theravance, Inc.
Recruiting - verified May 2013
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: aleglitazar; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

Condition: Clostridium Difficile-Associated Diarrhea (CDAD)
Interventions: Drug: fidaxomicin; Drug: placebo
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified May 2013
Adult Attention Deficit Hyperactivity Disorder

Condition: Adult Attention Deficit Hyperactivity Disorder
Interventions: Drug: SEP-225289; Drug: SEP-225289; Drug: Placebo
Sponsors: Sunovion; Sunovion
Recruiting - verified May 2013
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: Placebo; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures

Condition: Chronic Anal Fissures
Interventions: Drug: VEN 307; Drug: Placebo
Sponsors: Ventrus Biosciences, Inc; Ventrus Biosciences, Inc
Recruiting - verified May 2013
A Study of Evacetrapib in High-Risk Vascular Disease

Condition: Cardiovascular Diseases
Interventions: Drug: Evacetrapib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; The Cleveland Clinic
Recruiting - verified May 2013
Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects

Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab; Drug: 140 mg brodalumab; Drug: ustekinumab; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Oral Rivaroxaban in Children With Venous Thrombosis

Condition: Venous Thrombosis
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939); Other: Standard of care
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease

Condition: Diabetic Kidney Disease
Interventions: Drug: baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified May 2013
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Conditions: Prostate Cancer; Metastatic Castrate-Resistant Prostate Cancer; PSA
Interventions: Drug: OGX-427; Drug: Abiraterone Acetate; Drug: Prednisone
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; OncoGenex Technologies
Recruiting - verified May 2013
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: JNJ-38518168 (3 mg); Drug: JNJ-38518168 (10 mg); Drug: JNJ-38518168 (30 mg)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Efficacy and Safety of the PET Imaging Agent [18F]AZD4694 in Subjects With Probable Alzheimer's Disease

Condition: Alzheimer Disease
Intervention: Drug: [18F]AZD4694
Sponsors: Navidea Biopharmaceuticals; Navidea Biopharmaceuticals
Recruiting - verified April 2013
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin Therapy

Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec/liraglutide; Drug: liraglutide; Drug: exenatide
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
Study of BMS-936558 vs. Everolimus in Pre-Treated Advanced Or Metastatic Clear-cell RCC

Condition: Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Everolimus
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Co. Ltd
Recruiting - verified May 2013
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions: Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Interventions: Drug: pegylated liposomal doxorubicin (PLD); Drug: VTX-2337; Drug: Placebo
Sponsors: VentiRx Pharmaceuticals Inc.; VentiRx Pharmaceuticals Inc.; Gynecologic Oncology Group
Recruiting - verified April 2013
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium bromide; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Bevacizumab [Avastin]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)

Condition: Acute Coronary Syndrome
Interventions: Drug: SAR236553 (REGN727); Other: placebo
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas (NHL)

Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Conditions: Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: FOLFOX regimen; Drug: selumetinib
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)

Condition: Brain Metastases From Non-small Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Veliparib; Drug: Placebo
Sponsors: AbbVie; AbbVie (prior sponsor, Abbott)
Recruiting - verified April 2013
Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: MLN9708; Drug: Dexamethasone; Drug: Melphalan; Drug: Cyclophosphamide; Drug: Thalidomide; Drug: Lenalidomide
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2013
A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

Conditions: Deep Vein Thrombosis; Venous Thrombosis
Interventions: Drug: edoxaban tosylate; Drug: enoxaparin/unfractionated heparin; Drug: warfarin
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2013
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

Conditions: Adult Alveolar Soft-part Sarcoma; Adult Angiosarcoma; Adult Epithelioid Sarcoma; Adult Extraskeletal Chondrosarcoma; Adult Fibrosarcoma; Adult Leiomyosarcoma; Adult Liposarcoma; Adult Neurofibrosarcoma; Chondrosarcoma; Endometrial Stromal Sarcoma; Mast Cell Sarcoma; Metastatic Adult Malignant Fibrous Histiocytoma of Bone; Ovarian Carcinosarcoma; Ovarian Sarcoma; Recurrent Adult Malignant Fibrous Histiocytoma of Bone; Recurrent Adult Soft Tissue Sarcoma; Small Intestine Leiomyosarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003 AM5)

Conditions: Genital Warts; Anal Cancer; Anal Intraepithelial Neoplasia
Intervention: Biological: V503 Vaccine
Sponsors: Merck; Merck
Recruiting - verified May 2013
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: empagliflozin (low dose qd); Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Empagliflozin (high dose qd); Drug: empagliflozin (high dose bid); Drug: Placebo; Drug: empagliflozin (low dose bid)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2013
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)

Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib; Drug: imatinib (Gleevec/ Glivec)
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety of SAR236553 (REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Combo II)

Condition: Hypercholesterolemia
Interventions: Drug: SAR236553 (REGN727); Drug: matching placebo SAR236553 (REGN727); Drug: Ezetimibe; Drug: matching placebo for Ezetimibe
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

Condition: Cystic Fibrosis
Interventions: Drug: Aztreonam for Inhalation Solution (AZLI); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified July 2012
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Conditions: Inflammation; Rheumatoid Arthritis
Interventions: Drug: NNC0109-0012; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2013
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Condition: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Drug: fingolimod; Drug: copaxone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Study of Odanacatib When Administered to Adolescents Treated With Glucocorticoids (MK-0822-066)

Condition: Osteoporosis
Interventions: Drug: Odanacatib; Drug: Placebo to match odanacatib
Sponsors: Merck; Merck
Recruiting - verified April 2013
Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)

Condition: Asthma
Intervention: Device: Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)
Sponsors: American Lung Association Asthma Clinical Research Centers; American Lung Association Asthma Clinical Research Centers; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery

Conditions: Adult Angiosarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
Interventions: Biological: trebananib; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Condition: Ovarian Cancer
Interventions: Drug: Carboplatin; Drug: Gemcitabine; Drug: Carboplatin; Drug: Gemcitabine; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; University of Sydney; Australia New Zealand Gynaecological Oncology Group; Bionomics Limited
Recruiting - verified May 2013
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®; Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™); Biological: Kinrix®; Biological: Varivax®
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain

Condition: Osteoarthritis of the Knee
Interventions: Drug: NKTR-181; Drug: Placebo
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified May 2013
Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Condition: Management of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
Intervention: Biological: Darbepoetin alfa
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech
Recruiting - verified May 2013
Study to Determine the Efficacy and Safety of AMG 785 in the Treatment of Postmenopausal Women With Osteoporosis

Condition: Postmenopausal Women With Osteoporosis
Interventions: Drug: AMG 785; Drug: Alendronate
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo; Drug: Placebo; Drug: Sirukumab; Drug: Sirukumab; Drug: Sirukumab
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
A Study of Tabalumab in Participants With Previously Treated Multiple Myeloma (MM)

Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib; Drug: Bendamustine hydrochloride; Drug: Rituximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharmacyclics
Recruiting - verified May 2013
Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Condition: Breast Cancer
Interventions: Drug: BKM120 Matching placebo; Drug: Fulvestrant; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva

Condition: Vulvar Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: biopsy; Procedure: therapeutic conventional surgery; Radiation: intensity-modulated radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

Condition: Hypercholesterolemia
Interventions: Drug: PBO; Drug: 200mg PF-04950615 (RN316); Drug: 300mg PF-04950615 (RN316); Drug: PBO; Drug: PF-04950615; Drug: PF-04950615; Drug: PF-04950615
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Condition: Solid Tumors
Interventions: Drug: Iniparib (SAR240550/BSI-201); Drug: Carboplatin; Drug: Doxorubicin HCL liposome injection; Drug: Gemcitabine; Drug: Irinotecan; Drug: Paclitaxel; Drug: Topotecan
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Condition: Clostridium Difficile-associated Diarrhea
Intervention: Drug: fidaxomicin
Sponsors: Optimer Pharmaceuticals; Optimer Pharmaceuticals
Recruiting - verified April 2013
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine; Drug: Fosaprepitant Placebo; Drug: Dexamethasone; Drug: Ondansetron; Drug: Dexamethasone Placebo; Drug: Ondansetron Placebo; Drug: Rescue Therapy
Sponsors: Merck; Merck
Recruiting - verified May 2013
International Guillain-Barré Syndrome Outcome Study

Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2013
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Recruiting - verified May 2013
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Condition: Spasticity of the Upper and Lower Limb Due to Cerebral Causes
Intervention: Drug: IncobotulinumtoxinA
Sponsors: Merz Pharmaceuticals GmbH; Merz Pharmaceuticals GmbH
Recruiting - verified April 2013
Driveline Silicone Skin Interface Registry

Condition: Driveline Heart-assisted Device Related Infection
Intervention:
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Condition: Asthma
Interventions: Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4; Other: Placebo DPI; Drug: Flovent Diskus 250 mcg
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified April 2013
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

Condition: Smoking Cessation
Interventions: Drug: placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Conditions: Chronic Pain; Low Back Pain; Analgesia
Interventions: Drug: ALO-02; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

Condition: Colorectal Cancer Metastatic
Interventions: Drug: AFLIBERCEPT AVE0005; Drug: FOLFIRI
Sponsors: Sanofi; Sanofi; Regeneron Pharmaceuticals
Recruiting - verified May 2013
Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation

Condition: Menorrhagia
Interventions: Device: Aurora Endometrial Ablation; Device: Rollerball Ablation/Resection
Sponsors: Minerva Surgical, Inc.; Minerva Surgical, Inc.
Recruiting - verified May 2013
To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: STF 115469 Foam; Drug: Vehicle Foam
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone; Drug: Velcade plus dexamethasone
Sponsors: Onyx Pharmaceuticals; Onyx Pharmaceuticals
Recruiting - verified May 2013
To Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Calcipotriene 0.005%, Applied Under Maximal Use Conditions in 12-16 Year Olds With Plaque Psoriasis

Condition: Psoriasis
Intervention: Drug: calcipotriene
Sponsors: GlaxoSmithKline; Stiefel, a GSK Company; GlaxoSmithKline
Recruiting - verified April 2013
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
Study With the ConforMIS iDuo(R) G2

Condition: Bicompartmental Osteoarthritis
Intervention: Device: iDuo G2
Sponsors: ConforMIS, Inc.; ConforMIS, Inc.
Recruiting - verified April 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Other: Placebo Comparator
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2013
Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)

Condition: Irritable Bowel Syndrome
Interventions: Drug: JNJ-27018966; Drug: Placebo
Sponsors: Furiex Pharmaceuticals, Inc; Furiex Pharmaceuticals, Inc
Recruiting - verified May 2013
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH
Recruiting - verified May 2013
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Lisdexamfetamine dimesylate; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

Conditions: Trisomy 13; Trisomy 18; Trisomy 21; Aneuploidy
Intervention: Procedure: Blood Draw
Sponsors: Natera, Inc.; Natera, Inc.; Columbia University; George Washington University; National Institutes of Health (NIH)
Recruiting - verified May 2013
Registry for Severe ROP and Treatment on Visual Outcomes

Condition: Retinopathy of Prematurity
Intervention:
Sponsors: Pediatrix Medical Group; Pediatrix Medical Group
Recruiting - verified May 2013
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755 AM2)

Condition: Hepatitis C, Chronic
Interventions: Biological: peginterferon alfa-2a; Drug: ribavirin; Drug: boceprevir
Sponsors: Merck; Merck
Recruiting - verified May 2013
Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

Condition: Juvenile Idiopathic Arthritis
Interventions: Behavioral: Web-based coping skills training; Behavioral: Online disease education
Sponsors: Children's Mercy Hospital Kansas City; Children's Mercy Hospital Kansas City; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified May 2013
Mechanism and Repository Study for the Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Intervention:
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PPM3 175 mg eq.; Drug: PPM3 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid emulsion)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Ipilimumab
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified May 2013
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: afatinib; Drug: erlotinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Tivantinib in Treating Patients With Metastatic Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Drug: tivantinib; Other: placebo; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of RO4917523 in Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: RO4917523; Drug: RO4917523; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified May 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified April 2013
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB Pharma SA
Recruiting - verified April 2013
Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Condition: Psoriasis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Condition: Schizophrenia
Interventions: Drug: PP3M 175 mg eq.; Drug: PP3M 263 mg eq.; Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: Placebo (20% Intralipid); Drug: PP1M 50 mg eq.; Drug: PP1M 75 mg eq.; Drug: PP1M 100 mg eq.; Drug: PP1M 150 mg eq.
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2013
Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Castration Resistant Prostate Cancer; Pain; Prostatic Neoplasms
Interventions: Drug: cabozantinib; Drug: mitoxantrone; Drug: prednisone
Sponsors: Exelixis; Exelixis
Recruiting - verified May 2013
Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients

Condition: Ligneous Conjunctivitis
Intervention: Biological: Human Plasminogen
Sponsors: Kedrion S.p.A.; Kedrion S.p.A.
Recruiting - verified May 2013
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Condition: Hemophilia B
Intervention: Biological: rIX-FP
Sponsors: CSL Behring; CSL Behring
Recruiting - verified May 2013
Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2013
Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

Condition: Restless Legs Syndrome
Intervention: Drug: Rotigotine
Sponsors: UCB, Inc.; UCB BIOSCIENCES, Inc.
Recruiting - verified May 2013
Combining Lesinurad With Allopurinol in Inadequate Responders

Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2013
AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction

Condition: ST Segment Elevation Myocardial Infarction
Interventions: Biological: AMR-001; Other: placebo
Sponsors: Amorcyte, Inc.; Amorcyte, Inc.
Recruiting - verified February 2013
Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex

Condition: Cervical Dystonia
Intervention: Biological: Xeomin®
Sponsors: Merz Pharmaceuticals, LLC; Merz Pharmaceuticals, LLC
Recruiting - verified April 2013
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

Condition: Colorectal Cancer Metastatic
Intervention: Device: TheraSphere
Sponsors: Nordion (Canada) Inc.; Nordion (Canada) Inc.
Recruiting - verified May 2013
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Condition: Asthma
Interventions: Drug: Placebo; Drug: Flovent Diskus; Drug: Fluticasone propionate DPI Dose 1; Drug: Fluticasone propionate DPI Dose 2; Drug: Fluticasone propionate DPI Dose 3; Drug: Fluticasone propionate DPI Dose 4
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; PPD
Recruiting - verified April 2013
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: CC-486 plus Carboplatin; Drug: CC-486 plus ABI-007; Drug: CC-486
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2013
Study of Reduced Anti-coagulation/Anti-platelet Therapy in Patients With the HeartMate II Left Ventricular Assist System (LVAS) (TRACE)

Conditions: Anticoagulation; Left Ventricular Assist Device
Intervention:
Sponsors: Thoratec Europe Ltd; Thoratec Europe Ltd; Thoratec Corporation
Recruiting - verified May 2013
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol

Conditions: Hypercholesterolemia; Coronary Heart Disease
Interventions: Drug: mipomersen sodium 200 mg; Drug: Placebo; Drug: mipomersen sodium 70 mg
Sponsors: Genzyme; Genzyme
Recruiting - verified May 2013
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

Condition: Diabetic Peripheral Neuropathy
Interventions: Drug: Pregabalin; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Conditions: Heart Failure; Cardiac Failure; Acute Decompensated Heart Failure (ADHF)
Interventions: Device: Isolated veno-venous ultrafiltration (AQ); Drug: IV Loop Diuretics (LD)
Sponsors: Gambro Renal Products, Inc.; Gambro Renal Products, Inc.; Gambro UF Solutions, Inc.
Recruiting - verified May 2013
A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241 AM3)

Condition: Asthma
Interventions: Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Drug: Mometasone Furoate/Formoterol MDI 200/5 mcg; Drug: Mometasone Furoate MDI 100 mcg; Drug: Mometasone Furoate MDI 200 mcg; Drug: Albuterol 90 mcg /salbutamol 100 mcg HFA MDI; Drug: Prednisone/prednisolone
Sponsors: Merck; Merck
Recruiting - verified May 2013
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

Condition: Central Nervous System
Intervention: Drug: perampanel
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2013
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Conditions: Chronic Kidney Disease; Chronic Renal Failure
Interventions: Biological: Epoetin Hospira; Biological: Epogen (Amgen)
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified May 2013
GLORIA-AF Registry Program - Second and Third Phases

Conditions: Stroke; Atrial Fibrillation
Intervention:
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain

Condition: Neuropathic Pain
Interventions: Drug: SAR292833; Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Interventions: Drug: brentuximab vedotin; Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2013
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Condition: Epilepsy, Partial Seizures
Intervention: Drug: Pregabalin
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders

Condition: Smoking Cessation
Interventions: Drug: Placebo; Drug: varenicline tartrate; Drug: bupropion hydrochloride; Drug: Nicotine Replacement Therapy Patch
Sponsors: Pfizer; Pfizer; GlaxoSmithKline
Recruiting - verified May 2013
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified May 2013
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer

Condition: Gastric Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: capecitabine; Drug: cisplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Treatment Study of Sleep Apnea Among Patients With Transient Ischemic Attack and Minor Stroke

Conditions: Transient Ischemic Attack; Stroke
Interventions: Device: Standard CPAP Intervention; Behavioral: Enhanced CPAP Intervention
Sponsors: Yale University; Yale University; National Heart, Lung, and Blood Institute (NHLBI); Indiana University
Recruiting - verified April 2013
Vest Prevention of Early Sudden Death Trial and VEST Registry

Conditions: Myocardial Infarction; Ventricular Dysfunction; Sudden Death; Ventricular Tachycardia; Ventricular Fibrillation
Intervention: Device: wearable defibrillator
Sponsors: University of California, San Francisco; University of California, San Francisco; Zoll Medical Corporation
Recruiting - verified April 2013
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects

Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Conditions: Vaccines; Meningococcal Vaccines
Interventions: Biological: rLP2086 and Gardasil; Biological: rLP2086; Biological: Gardasil
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Condition: Asthma
Interventions: Drug: Symbicort pMDI; Drug: Symbicort pMDI; Drug: budesonide pMDI; Drug: budesonide pMDI
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2013
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)

Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified May 2013
Open Label Study of Long Term Evaluation Against LDL-C Trial

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: SPD489 (Lisdexamfetamine dimesylate ); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

Condition: Major Depressive Disorder
Interventions: Drug: Antidepressant + SPD489 (Lisdexamfetamine dimesylate ); Drug: Antidepressant + Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2013
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Condition: Hepatorenal Syndrome
Interventions: Drug: 5mg Ifetroban Injection; Drug: 15mg Ifetroban Injection; Drug: 50mg Ifetroban Injection; Drug: 150mg Ifetroban Injection; Other: 5% Dextrose in Water
Sponsors: Cumberland Pharmaceuticals; Cumberland Pharmaceuticals
Recruiting - verified April 2013
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions: Infection; Hypertension; Anesthesia; Pain; Reflux
Intervention: Drug: Ampicillin
Sponsors: Duke University; Daniel Benjamin; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); The EMMES Corporation
Recruiting - verified May 2013
Chondrofix Osteochondral Allograft Prospective Study

Conditions: Articular Cartilage Disorder; Degeneration; Articular Cartilage; Chronic Cartilage Injury; Acute Cartilage Injury; Defect of Articular Cartilage
Intervention: Procedure: Chondrofix Osteochondral Allograft
Sponsors: Zimmer Orthobiologics, Inc.; Zimmer Orthobiologics, Inc.
Recruiting - verified May 2013
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas

Conditions: Neurofibromatosis; NF1; Plexiform Neurofibromas
Intervention: Drug: Sutent®/Sunitinib
Sponsors: Indiana University; Indiana University; Department of Defense; Pfizer
Recruiting - verified May 2013
Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression

Condition: Depression, Bipolar
Interventions: Drug: Placebo; Drug: Cariprazine; Drug: Cariprazine; Drug: Cariprazine
Sponsors: Forest Laboratories; Forest Laboratories; Gedeon Richter Ltd.
Recruiting - verified April 2013
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Conditions: Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: veliparib; Other: hydrocortisone/placebo; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2013
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2013
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Interventions: Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Desvenlafaxine Succinate Sustained-Release; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Condition: Major Depressive Disorder
Intervention: Drug: DVS SR
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2013
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2013
The Evaluation of VAD InterVEntion Before Inotropic Therapy

Condition: Congestive Heart Failure
Interventions: Device: HM II® (HeartMate II® LVAD); Other: OMM (Optimal Medical Management)
Sponsors: University of Michigan; University of Michigan; National Heart, Lung, and Blood Institute (NHLBI); Thoratec Corporation
Not yet recruiting - verified May 2013
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome

Condition: Fragile X Syndrome
Interventions: Drug: AFQ056; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Condition: Meningitis, Meningococcal
Interventions: Biological: rLP2086 vaccine; Biological: control
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
S0820, Adenoma and Second Primary Prevention Trial

Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting - verified May 2013
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

Condition: Urothelial Carcinoma
Interventions: Biological: DN24-02; Other: Standard of Care
Sponsors: Dendreon; Dendreon
Recruiting - verified April 2013
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma

Conditions: Cancer; Hematologic Malignancies; Multiple Myeloma; Oncology; Bone Metastases; Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab; Drug: Zoledronic acid
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2013
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2013
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Condition: Atrophy, Geographic
Interventions: Drug: GSK933776; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2013
Hydrocortisone for BPD

Conditions: Infant, Newborn; Infant, Small for Gestational Age; Infant, Very Low Birth Weight; Infant, Premature; Bronchopulmonary Dysplasia
Interventions: Drug: Hydrocortisone; Drug: Placebo
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR)
Recruiting - verified May 2013
A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD

Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol; Drug: Vilanterol; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V; Biological: PROSTVAC-F; Drug: GM-CSF; Other: GM-CSF Placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified February 2013
Pilon Fracture Reduction and Functional Outcome

Condition: Pilon Fracture of Tibia
Intervention:
Sponsors: AO Clinical Investigation and Documentation; AO Clinical Investigation and Documentation
Recruiting - verified April 2013
Smoking Cessation Study In Healthy Adolescent Smokers

Condition: Smoking Cessation
Interventions: Drug: Varenicline 1mg BID; Drug: Varenicline 0.5mg BID; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves

Condition: Symptomatic Severe Aortic Stenosis
Interventions: Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: AVR with a surgical heart valve; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis; Device: TAVR Implantation of the Transcatheter Aortic Valve Prosthesis
Sponsors: Edwards Lifesciences; Edwards Lifesciences
Recruiting - verified April 2013
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified April 2013
Open-Label Extension Study of GSK1605786A

Condition: Crohn's Disease
Intervention: Drug: GSK1605786A
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2013
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2013
Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Condition: Depression
Interventions: Drug: Armodafinil; Drug: Placebo
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2013
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

Condition: Warfarin Therapy
Intervention: Device: Warfarin GenoSTAT Test
Sponsors: Iverson Genetic Diagnostics, Inc.; Iverson Genetic Diagnostics, Inc.
Recruiting - verified May 2013
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: MM-302 Monotherapy; Drug: MM-302 in combination with trastuzumab; Drug: MM-302 in combination with trastuzumab q3w; Drug: MM-302 in combination with trastuzumab and cyclophosphamide
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2013
INcrease Of VAgal TonE in CHF

Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Myelodysplasia
Interventions: Biological: human myeloid progenitor cells; Drug: G-CSF
Sponsors: Cellerant Therapeutics; Cellerant Therapeutics; Department of Health and Human Services
Recruiting - verified May 2013
Effects of Increased, Egg-Based Protein Intake on Muscle Composition, Metabolic Health and Systemic Inflammation in Obese, Older Adults

Conditions: Muscle Composition and Muscle Size.; Metabolic Health Status.; Muscle Inflammatory Status.
Intervention: Dietary Supplement: Dietary Protein Intake
Sponsors: Purdue University; Purdue University
Recruiting - verified May 2013
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified May 2013
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Biological: IMC-3C5
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2013
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Condition: Crohn's Disease
Interventions: Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection; Drug: PF-04236921 SC injection
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Phase 1 Study of LY2787106 in Cancer and Anemia

Condition: Anemia
Interventions: Drug: LY2787106; Dietary Supplement: Iron Supplementation
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Conditions: Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma
Interventions: Biological: ofatumumab; Drug: bendamustine hydrochloride; Drug: bortezomib; Other: laboratory biomarker analysis; Procedure: positron emission tomography with radiolabeled targeting agents; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2013
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: docetaxel; Drug: cyclophosphamide; Biological: trastuzumab; Drug: paclitaxel; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Conditions: Neurofibromatosis; NF1; Neurofibromas
Intervention: Drug: Tasigna
Sponsors: Indiana University; Indiana University; Novartis
Recruiting - verified May 2013
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Conditions: Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma

Condition: Malignant Melanoma
Interventions: Drug: vemurafenib; Drug: GDC-0973
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

Condition: Post Herpetic Neuralgia
Interventions: Drug: Pregabalin; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2013
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

Conditions: Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Biological: cetuximab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: alemtuzumab; Drug: dasatinib; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: in vitro-treated peripheral blood stem cell transplantation; Drug: dexamethasone; Drug: cyclophosphamide; Biological: filgrastim; Biological: pegfilgrastim; Drug: methotrexate; Drug: leucovorin calcium; Drug: melphalan; Drug: tacrolimus; Drug: etoposide phosphate; Drug: cytarabine; Drug: mercaptopurine; Drug: vincristine sulfate; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM3)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2013
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Conditions: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM4)

Condition: Bipolar Disorder, Pediatric
Interventions: Drug: asenapine; Drug: Placebo to match asenapine; Drug: Rescue medication
Sponsors: Merck; Merck
Recruiting - verified May 2013
Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and Older

Conditions: Epilepsy; Monotherapy
Interventions: Drug: Lacosamide; Drug: Carbamazepine-Controlled Release
Sponsors: UCB, Inc.; UCB BIOSCIENCES GmbH; EDEV S.À.R.L
Recruiting - verified May 2013
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: Alliance for Clinical Oncology Trials; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified April 2013
Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified May 2013
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

Condition: Fibromyalgia
Interventions: Drug: Duloxetine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Conditions: Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Spinal Cord Neoplasm; Untreated Childhood Brain Stem Glioma; Untreated Childhood Cerebral Astrocytoma
Interventions: Drug: vorinostat; Biological: bevacizumab; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin; Drug: Rituximab; Drug: rituximab + gemcitabine; Drug: rituximab +bendamustine
Sponsors: Pfizer; Pfizer; UCB, Inc.
Recruiting - verified May 2013
Alzheimer's Disease Neuroimaging Initiative 2

Conditions: Mild Cognitive Impairment (MCI); Alzheimer's Disease
Intervention:
Sponsors: Alzheimer's Disease Cooperative Study (ADCS); Alzheimer's Disease Cooperative Study (ADCS); Northern California Institute for Research and Education (NCIRE); National Institute on Aging (NIA)
Recruiting - verified May 2013
A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease

Condition: Alzheimer Disease
Interventions: Drug: gantenerumab; Drug: gantenerumab; Drug: placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2013
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Condition: Glioma
Interventions: Drug: LY2157299; Drug: Radiation; Drug: Temozolomide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2013
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Conditions: Transitional Cell Carcinoma; Bladder Carcinoma; Urothelial Carcinoma
Interventions: Drug: Everolimus; Drug: Everolimus; Drug: Paclitaxel
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Novartis Pharmaceuticals
Recruiting - verified May 2013
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified May 2013
Growth of Infants Fed an Extensively Hydrolyzed Infant Formula

Condition: Growth
Interventions: Other: Extensively hydrolyzed whey infant formula; Other: Extensively hydrolyzed casein infant formula
Sponsors: Nestlé; Nestlé
Recruiting - verified May 2013
Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer

Conditions: Recurrent Thyroid Cancer; Stage I Follicular Thyroid Cancer; Stage I Papillary Thyroid Cancer; Stage II Follicular Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage III Follicular Thyroid Cancer; Stage III Papillary Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Condition: Ischemic Stroke
Interventions: Drug: PF-03049423; Drug: PF-03049423; Drug: PF-03049423; Other: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107 AM1)

Condition: Arthritis, Rheumatoid
Interventions: Drug: Etoricoxib 60 mg; Drug: Etoricoxib 90 mg; Drug: Placebo to Etoricoxib 60 mg; Drug: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects

Condition: Post Operative Pain
Intervention: Drug: oxymorphone HCl
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified May 2013
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2013
A Study of LY2127399 in Patients With Systemic Lupus Erythematosus

Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2013
Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma

Condition: Non-Hodgkin's Lymphoma (NHL)
Interventions: Drug: temsirolimus; Drug: temsirolimus
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Bendamustine; Drug: Doxorubicin; Drug: Bortezomib; Drug: Bendamustine; Drug: Filgrastim
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Cephalon
Recruiting - verified May 2013
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2013
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH-II)

Condition: Intracerebral Hemorrhage
Intervention: Drug: Nicardipine hydrochloride
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2013
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Conditions: Light Chain Deposition Disease; Smoldering Multiple Myeloma
Interventions: Other: clinical observation; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Condition: Hypertension, Pulmonary
Interventions: Drug: ambrisentan; Drug: tadalafil
Sponsors: GlaxoSmithKline; GlaxoSmithKline; Gilead Sciences
Recruiting - verified May 2013
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi; Sanofi
Recruiting - verified May 2013
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

Conditions: Venous Thrombosis; Pediatrics
Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Sponsors: Bayer; Bayer; Janssen Research & Development, LLC
Recruiting - verified May 2013
Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

Conditions: Keratoconus; Post-Refractive Ectasia
Intervention: Device: UVX Light
Sponsors: Price Vision Group; Price Vision Group
Recruiting - verified May 2013
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2013
A Study of IMC-RON8 in Advanced Solid Tumors

Condition: Cancer
Interventions: Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2013
Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207127; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: Ribavirin; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: BI 201335; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin; Drug: BI 207217; Drug: BI 201335; Drug: BI 207127; Drug: Ribavirin; Drug: BI 207127; Drug: BI 201335; Drug: Ribavirin; Drug: Ribavirin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2013
Cediranib and Olaparib in Combination for Recurrent Ovarian or Triple-Negative Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Ovarian Endometrioid Adenocarcinoma; Ovarian Papillary Serous Carcinoma; Ovarian Serous Cystadenocarcinoma; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Triple-negative Breast Cancer
Interventions: Drug: olaparib; Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified May 2013
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections

Condition: Complicated Urinary Tract Infections or Pyelonephritis
Interventions: Drug: doripenem; Drug: doripenem placebo; Drug: cefepime; Drug: cefepime placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial

Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Selexipag (ACT-293987); Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified May 2013
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Conditions: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2013
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

Condition: Intraabdominal Infections
Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039); Drug: Ertapenem, Amoxicillin/clavulanate
Sponsors: Bayer; Bayer
Recruiting - verified April 2013
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Conditions: Advanced Malignant Mesothelioma; Epithelial Mesothelioma; Recurrent Malignant Mesothelioma; Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium; Drug: cisplatin; Drug: cediranib maleate; Other: placebo
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Condition: Heart Failure With Reduced Ejection Fraction
Interventions: Drug: LCZ696 200 mg BID; Drug: Enalapril 10 mg BID
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2013
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified May 2013
Evaluation of the Artus® CMV PCR Test

Condition: Cytomegalovirus Infections
Intervention:
Sponsors: QIAGEN Gaithersburg, Inc; QIAGEN Gaithersburg, Inc
Recruiting - verified April 2013
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: Coreg CR®; Drug: lisinopril; Other: placebo
Sponsors: University of South Florida; University of South Florida; National Cancer Institute (NCI)
Recruiting - verified January 2013
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi
Recruiting - verified May 2013
Red Cell Storage Duration Study

Conditions: Cardiac Surgery; Erythrocyte Transfusion
Interventions: Biological: Red blood cell units stored <= 10 days; Biological: Red blood cell units stored >= 21 days
Sponsors: New England Research Institutes; New England Research Institutes; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2013
Stem Cell Related Donor Safety Study

Condition: Related Hematopoietic Stem Cell Donors
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Institutes of Health (NIH); University of Utah; University of Pittsburgh
Recruiting - verified May 2013
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Prostate Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: cisplatin; Other: placebo; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Conditions: Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine; Drug: 5-Azacytidine
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2013
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2013
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2013
Cross Linking for Treatment of Corneal Infection

Condition: Infectious Keratitis
Interventions: Drug: riboflavin; Device: UVX Light
Sponsors: Price Vision Group; Price Vision Group; Cornea Research Foundation of America
Recruiting - verified May 2013
The MagnaSafe Registry: Determining the Risks of Magnetic Resonance Imaging (MRI) in the Presence of Pacemakers and Implantable Cardioverter Defibrillators (ICDs)

Conditions: Need for MRI Imaging With Pacemaker or; Implantable Cardioverter Defibrillator Implanted
Intervention: Device: MRI with pacemaker or ICD
Sponsors: Scripps Health; Scripps Health; The Scripps Foundation; The Hewitt Medical Research Foundation; St. Jude Medical; Boston Scientific Corporation; Biotronik, Inc.
Recruiting - verified August 2012
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Atypical Endocervical Glandular Cell of Undetermined Significance; Atypical Endometrial Hyperplasia; Atypical Glandular Cell of Undetermined Significance; Cervical Cancer; Cervical Intraepithelial Neoplasia Grade 2; Cervical Intraepithelial Neoplasia Grade 3; Human Papilloma Virus Infection
Intervention: Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified April 2013
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Condition: Advanced Solid Malignancies
Intervention: Drug: REGN421(SAR153192)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi
Recruiting - verified May 2013
PDE5 Inhibitor Use and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)

Condition: Anterior Ischemic Optic Neuropathy
Intervention: Drug: Diagnostic procedures
Sponsors: Bayer; Bayer
Recruiting - verified May 2013
Study of Endothelial Keratoplasty Outcomes

Conditions: Fuchs' Endothelial Corneal Dystrophy; Bullous Keratopathy; Iridocorneal Endothelial Syndrome; Posterior Polymorphous Dystrophy
Intervention: Procedure: endothelial keratoplasty
Sponsors: Cornea Research Foundation of America; Cornea Research Foundation of America
Recruiting - verified May 2013
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified May 2013
AngelMed for Early Recognition and Treatment of STEMI

Conditions: Acute Myocardial Infarction (AMI); Coronary Occlusion; Acute Coronary Syndrome
Intervention: Device: AngelMed Guardian System
Sponsors: Angel Medical Systems; Angel Medical Systems; Symbios Clinical
Recruiting - verified May 2013
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions: Deep Vein Thrombosis; Venous Thrombosis; Postphlebitic Syndrome; Venous Thromboembolism; Post Thrombotic Syndrome
Intervention: Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors: Washington University School of Medicine; Washington University School of Medicine; McMaster University; Ontario Clinical Oncology Group (OCOG); National Heart, Lung, and Blood Institute (NHLBI); BSN Medical Inc; Genentech; Covidien; BayerHealthcare; Mid America Heart Institute; Society of Interventional Radiology Foundation; Massachusetts General Hospital
Recruiting - verified May 2013
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Conditions: Stage IIIB Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: sunitinib malate; Other: placebo; Procedure: quality-of-life assessment; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Conditions: Psychotic Depression; Major Depression With Psychotic Features; Psychosis
Interventions: Drug: mifepristone; Drug: placebo
Sponsors: Corcept Therapeutics; Corcept Therapeutics
Recruiting - verified April 2013
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Conditions: Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: melphalan; Drug: prednisone; Drug: thalidomide; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia
Interventions: Radiation: Total Body Irradiation; Drug: Thiotepa; Drug: Fludarabine; Biological: Rabbit ATG; Drug: Palifermin
Sponsors: Indiana University; Indiana University
Recruiting - verified May 2013
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Recruiting - verified May 2013
Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells; Drug: Placebo
Sponsors: Osiris Therapeutics; Osiris Therapeutics
Recruiting - verified May 2013
Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

Condition: Lumbar Degenerative Disc Disease
Interventions: Device: DIAM™ Spinal Stabilization System; Procedure: Conservative care
Sponsors: Medtronic Spinal and Biologics; Medtronic Spinal and Biologics
Recruiting - verified April 2013
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified May 2013
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Conditions: Mycoses; Candidiasis, Invasive; Candidemia
Interventions: Drug: Isavuconazole; Drug: Caspofungin; Drug: Voriconazole
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Basilea Pharmaceutica
Recruiting - verified May 2013
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2013
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: Children's Oncology Group; Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2013
Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer

Conditions: Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI)
Recruiting - verified May 2013
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2013
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Stage IB Cervical Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage IVA Cervical Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); NCIC Clinical Trials Group
Recruiting - verified May 2013
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: paclitaxel poliglumex; Other: clinical observation
Sponsors: Gynecologic Oncology Group; Gynecologic Oncology Group; National Cancer Institute (NCI); CTI
Recruiting - verified May 2013
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2013

Find Paid Research Studies in Advance, Indiana

Welcome to Paid Research Studies.